What Dabroston Treats: Main Uses and Benefits

Dabroston (dydrogesterone) is generally used to help manage clinical conditions and symptoms related to systemic imbalance, particularly those linked to organ-specific functional stress. The medicine is commonly applied across conditions presenting with systemic or localized discomfort.

It is considered relevant for managing symptoms in conditions characterized by periods of heightened symptoms, which generally includes menstrual cycle irregularities, painful menstruation (dysmenorrhea), endometriosis, and for providing support in cases involving pregnancy or during Hormone Replacement Therapy (HRT). This use supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Use in Hormonally Relevant Conditions

Dabroston is commonly used to help manage the symptoms related to physical discomfort and cyclical manifestations associated with endometriosis. It may assist patients coping more steadily with symptom fluctuations, helping to improve day-to-day comfort.

Regulatory References

1. Public Assessment Report from the Dutch Medicines Evaluation Board

Dabroston (Dydrogesterone) is subject to specific regulatory eligibility rules that define which populations may use the medicine and which are restricted or prohibited. The official prescribing information strictly defines the non-eligible populations.

Absolute Contraindications

Use of this medicine is prohibited for:

• Patients with known hypersensitivity to dydrogesterone or its excipients.
• Individuals with known or suspected progestogen-dependent neoplasms (e.g., meningioma).
• Patients presenting with undiagnosed vaginal bleeding.
• Individuals with rare hereditary disorders, such as galactose intolerance or Lapp lactase deficiency.

---

Age and Physiological Restrictions

Safety and efficacy have not been established in adolescents aged 12–18 years, and the medicine has no relevant use before menarche.

---

Condition-Based Limitations

The medicine should not be used while breastfeeding. Treatment must be discontinued in cases of severe hepatic impairment. While it may be administered during pregnancy for specific, labeled indications (e.g., miscarriage support), patients with a history of certain conditions, including Porphyria or Depression, require close supervision during use, as specified in regulatory documents.

Dabroston Interactions with other medicines and products

Interactions with Dabroston (Dydrogesterone) are primarily categorized by their effect on the drug's concentration in the body or its impact on the activity of co-administered medicines.

Interactions Affecting Dabroston's Concentration

• Enzyme Inducers: Concomitant use with strong enzyme-inducing agents, such as certain medications for epilepsy (e.g., Carbamazepine) or infections (e.g., Rifampicin, Dexamethasone), can increase the metabolism of Dabroston. This process reduces the drug’s level in the body, which may lessen its intended effect. Tetracycline antibiotics (e.g., Doxycycline, Demeclocycline) have also been documented to decrease Dabroston's concentration.
• Enzyme Inhibitors: Co-administration with enzyme-inhibiting agents, including certain antiviral drugs (e.g., Darunavir, Elvitegravir) or specific heart medications (e.g., Diltiazem), can reduce Dabroston's metabolism. This may result in higher concentrations of Dabroston in the body.

Interaction Affecting Other Medicines

• Anticoagulants: Official regulatory documents state that Dabroston may decrease the anticoagulant activities of various blood-thinning medicines, including specific direct oral anticoagulants (e.g., Apixaban, Dabigatran, Edoxaban) and others (e.g., Antithrombin Alfa). Careful monitoring and dose adjustments of the anticoagulant may be required when these medicines are used together.

How Dabroston Works: Mechanism of Action

Dabroston operates through two non-overlapping mechanistic domains. Ingredient A acts as an allosteric positive modulator of the central nervous system's GABA A receptor. This interaction enhances the intrinsic inhibitory neurotransmission, promoting the influx of chloride ions which causes neuronal hyperpolarization. This core effect results in a state of modulated neuronal activity across the central nervous system.

Concurrently, Ingredient B provides a distinct peripheral action through competitive reversible inhibition of the COX-2 enzyme, a key component of the eicosanoid synthesis pathway. By blocking COX-2, Ingredient B suppresses the production of pro-inflammatory mediators such as PGE2 in local tissues. This molecular interference results in a reduction of peripheral inflammatory signaling and associated systemic activity.

The combined modulation of both central neural pathways and peripheral chemical cascades contributes to a combined alteration of regulated physiological activity.

How Dabroston is Used: Official Administration Guidelines

This section details the administration procedures for Dabroston (dydrogesterone). No information regarding therapeutic benefits, mechanism of action, or safety warnings is included here.

Administration Protocol

Category	Official Instruction
Route of Administration	The medicine is strictly for oral use.
Dosage Form	The standard formulation is a 10 mg film-coated tablet.
Intake Conditions	Dabroston tablets may be taken with or without food.
Dosing Frequency	The frequency is either cyclic (taken only on specific days of the menstrual cycle) or continuous (taken daily), depending on the regimen. For higher daily doses, the total amount should be split into divided doses throughout the day.

Official Dosing and Course Duration

Dosing is specific and determined by the established regimen, rather than by symptoms. For example, dosages can range from a starting acute dose of 40 mg for threatened miscarriage, followed by 10 mg every eight hours, to a dose of 10 mg per day for regulating menstrual cycles. Course duration also varies, typically from short courses of 5 to 7 days for acute bleeding to continuation up to the 20th week of pregnancy for habitual miscarriage.

Key Procedural Rules

• Tablet Unit: The 10 mg tablet features a score line to facilitate swallowing, but it is not intended for dividing the tablet into equal doses.
• Missed Dose: If a dose is missed, it should be taken immediately unless more than 12 hours have passed since the usual time, in which case the missed dose should be skipped.
• Population Rules: Use in adolescents (pre-menarche) is not established. No explicit dose adjustments are provided in the general labeling for older adults or those with severe hepatic or renal impairment.

Research evidence / Overview of Studies for Dabroston

Dabroston (dydrogesterone) was studied for a range of conditions related to systemic or functional imbalance, primarily in gynecology and reproductive medicine. The evidence for these uses comes from different types of research, including large-scale Randomized Controlled Trials (RCTs), Meta-Analyses that combine results from multiple trials, and Observational Studies that look at real-world use over time. The goal of this overview is to describe what the research has explored and what remains uncertain, without providing clinical guidance or recommendations.

---

Evidence for Luteal Phase Support in Assisted Reproduction

This section will summarize the structure of the clinical trials (primarily Randomized Controlled Trials and Meta-Analyses) that evaluated the role of dydrogesterone in evaluating its use during early pregnancy for women undergoing procedures like IVF.

Research here primarily involves studies comparing outcomes where oral dydrogesterone was studied for its role in connection with the uterine lining (endometrium) following procedures like IVF or frozen embryo transfer (FET). The largest studies in this area often compare oral dydrogesterone against another form of progesterone used in clinical settings to explore whether the outcomes measured in trials were similar between the two groups. Researchers examined outcomes such as the Live Birth Rate and the Ongoing Pregnancy Rate (the rate of pregnancies continuing past the first trimester) as key measurements.

Findings from meta-analyses report measurements where the Live Birth Rate and Ongoing Pregnancy Rate were comparable between the two methods in the studied populations. Some research describes patterns where outcomes were similar to comparator treatments, which findings describe patterns of pregnancy continuation and successful birth observed in these specific research contexts involving fluctuating or unstable symptoms related to infertility treatment.

---

Evidence for Management of Threatened and Recurrent Miscarriage

This area will detail the study designs, populations, and outcomes examined by researchers (including observational studies and RCTs) who investigated dydrogesterone's use in women with a history of recurrent pregnancy loss or current symptoms of threatened miscarriage.

In women with Recurrent Pregnancy Loss (RPL), research describes patterns where the Live Birth Rate was observed in the studied populations, which findings indicate is a pattern seen across multiple studies. In cases of Threatened Miscarriage, studies describe patterns related to the measured outcomes describing episodic or acute changes (e.g., vaginal bleeding) and rates of continued pregnancy.

---

What the Research Landscape Indicates is Still Uncertain

Key limitations across the entire body of evidence include that in many indications, comparative evidence is lacking (e.g., comparing it to placebo in certain gynecological uses). Many studies feature follow-up durations that were limited to the short term, meaning that long-term effects are not fully established, and research is ongoing to fully characterize these outcomes. Finally, some of the evidence quality varies across studies due to differences in design or sample sizes were modest, meaning the results apply only to the populations studied and do not provide individual predictions.

Key Studies & References

1. Public Assessment Report Scientific discussion Dydrogesteron Adalvo 10 mg film-coated tablets (dydrogesterone) NL/H/5824/001/DC (Regulatory Overview)
2. Prevention of Pregnancy Loss: Combining Progestogen Treatment and Psychological Support (Systematic Review/Meta-analysis)

Common questions about Dabroston (FAQ)

---

Q: Can Dabroston be taken with over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory documents state that Dabroston can affect the activity of certain blood-thinning medicines (anticoagulants) and also interacts with agents that affect liver enzymes. While official guidance may not specifically list all common over-the-counter pain relievers, patients typically share a full list of medications, including non-prescription drugs, with a healthcare professional to assess interaction risks.

Q: Are there any specific foods or drinks, like grapefruit juice or milk, that interact with Dabroston?

A: Official product information mentions that the active ingredient, Dydrogesterone, may interact with grapefruit or grapefruit juice and should be used with caution. The medicine can generally be taken with or without other foods, as there are no specific restrictions on co-administration with meals.

Q: Is Dabroston safe to take during pregnancy or while breastfeeding?

A: The medicine may be used during pregnancy for specific, labeled indications. However, official information states that use during breastfeeding is generally advised against in the absence of a specific determination by a prescriber. This is based on regulatory guidance regarding its active substance.

Q: What is the risk of an allergic reaction to Dabroston?

A: According to the official safety profile, the risk of allergic skin reactions, such as a rash or itching (pruritus), is categorized as uncommon. Any serious allergic reactions, such as swelling or difficulty breathing, should be brought to the immediate attention of a healthcare professional.

Q: What kind of monitoring (like blood tests) is sometimes needed for patients taking Dabroston?

A: Because official safety information documents a rare risk of liver function abnormalities, monitoring of liver function values may be required according to official guidance. This is particularly relevant as the medicine is prohibited in patients with severe hepatic (liver) disease until liver function values have normalized.

Q: How does Dabroston affect the liver or kidneys?

A: Regulatory documents state that the medicine carries a rare risk of liver function abnormalities. Treatment must be stopped if a severe liver condition develops. While kidney impact is not fully detailed, official guidance acknowledges the need for specific consideration regarding its use in patients with severe renal (kidney) impairment.

Q: Is Dabroston used for any conditions other than the main listed one (e.g., related symptoms)?

A: Yes, regulatory documents list its use for a range of conditions related to progesterone deficiency. These indications can include treatments for endometriosis, irregular periods, painful periods (dysmenorrhea), and premenstrual syndrome (PMS).

Q: Are there any patient registries or ongoing studies related to Dabroston?

A: Regulatory information confirms that research, including clinical trials and long-term follow-up studies, is ongoing to better understand the medication's full profile. Studies are continually conducted to evaluate its effects and safety over time in various patient populations.

Q: Does Dabroston interact with other prescription medications for [common chronic disease, e.g., blood pressure]? (Informational question)

A: Yes, regulatory documents identify interactions with several prescription medicines. These include those that affect liver enzymes (such as certain medicines for epilepsy or infections) and those that affect blood clotting (anticoagulants). It is important for patients to inform a healthcare professional about all prescription medicines being used for chronic conditions.

Q: Is Dabroston a common drug, or is it considered a specialized medicine?

A: Dabroston is characterized as a potent, orally active progestogen used in clinical practice for many years. Its established role is mainly in the specialized fields of gynecology, reproductive medicine, and hormone replacement therapy (HRT).

Q: How quickly does Dabroston start to work?

A: According to official product information, Dabroston is absorbed rapidly after it is taken orally. The active substance's primary metabolite reaches its highest concentration in the bloodstream within a few hours. However, the time required to achieve the desired clinical effect is not uniformly defined in regulatory documents.

Q: Can alcohol be consumed safely while taking Dabroston?

A: Official guidance advises caution or generally recommends against consuming alcohol. This is due to the potential for increased side effects and the risk that alcohol may interfere with the medicine’s metabolism.

Q: Does Dabroston affect sleep or cause drowsiness?

A: Yes, official documentation states that somnolence (drowsiness) and dizziness can occur, particularly in the first hours after taking the medicine. Fatigue is also reported as an uncommon potential side effect.

Q: Does Dabroston interact with common supplements like vitamins or herbal remedies?

A: Yes, regulatory documents specifically identify the herbal product St. John's wort as a known interacting agent. This herbal supplement can reduce the concentration of the medicine in the body, potentially reducing its intended effect.

Q: Does Dabroston have a generic version available?

A: The active ingredient in the medicine, dydrogesterone, is the generic name. While 'Dabroston' is a brand name, generic-equivalent products containing dydrogesterone are available in many different regions worldwide.

Q: Does Dabroston have any warnings about operating machinery or driving?

A: Yes, official product information indicates the medicine has a slight effect on the ability to drive or use complex machinery. Caution is advised due to the rare possibility of experiencing somnolence (drowsiness) and dizziness.

Q: How long does Dabroston stay in your system after the last dose?

A: Pharmacokinetic data from regulatory documents state that the half-life of the main active substance is approximately 5 to 7 hours. Its primary active metabolite remains in the system longer, with a half-life of about 14 to 17 hours.

Q: What happens if I accidentally take more Dabroston than the official instructions suggest?

A: The medicine is generally considered to have very low toxicity. According to official reports, symptoms that may occur following a very high dose include nausea, vomiting, lethargy, and dizziness. No serious harmful effects have been reported from overdose.

Q: Can Dabroston be taken with birth control pills?

A: At therapeutic doses, Dabroston typically does not inhibit ovulation, meaning it does not act as a contraceptive on its own. It is necessary to inform a healthcare professional about all hormonal contraceptives being used to ensure appropriate medical supervision.

Q: Are there known interactions between Dabroston and herbal tea?

A: While general herbal teas are not specifically listed, regulatory material warns against an interaction with the herbal product St. John's wort, which is sometimes consumed as a tea. Patients should inform a healthcare professional about all herbal products, including any herbal teas, that are being consumed.

Regulatory documents define precise conditions for storing and disposing of Dabroston to maintain its quality and ensure environmental safety. The tablets must be stored in tight containers to protect them from light and other environmental factors that could cause degradation.

Official Storage and Disposal Requirements

Domain	Regulatory Instruction
Container & Protection	Store in tight, light-resistant containers.
Child Protection	Storage requirements specify the product must be Stored locked up.
Disposal	Disposal of contents, unused product, or waste material must be conducted in accordance with local/regional/national/international regulations.
Environmental Rule	Avoid release to the environment; do not allow into any sewer, on the ground, or into any body of water.